Crossmark

Five-alpha reductase inhibitors in men undergoing active surveillance for prostate cancer: impact on treatment and reclassification after 6 years follow-up

Crossref DOI link: https://doi.org/10.1007/s00345-021-03644-2

Published Online: 2021-03-08

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ashrafi, Akbar N. https://orcid.org/0000-0001-7519-4055
Shin, Toshitaka

Marien, Arnaud

Clifford, Thomas

Shoji, Sunao

Iwata, Tsuyoshi

Iwata, Atsuko

Oishi, Masakatsu

Chopra, Sameer

Cai, Jie

Ukimura, Osamu

Bahn, Duke

Gill, Inderbir S.

Abreu, Andre Luis
License Information

Text and Data Mining valid from 2021-03-08

Version of Record valid from 2021-03-08
More Information

Article History

Received: 19 October 2020

Accepted: 19 February 2021

First Online: 8 March 2021

Research involving human participants and/or animals (ethical approval)

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below